טלזנה 1 מ"ג - Talzenna 1 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||
| צ×רת ××× ×× | קפס××× ×§×©×××, CAPSULE, HARD ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. | ||||||||||||||||||
| |||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××× × 1 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | PFIZER INC., USA |
| ×©× ××¢× ×ר×ש×× | PFIZER PHARMACEUTICALS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 4/2019. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 15/09/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־16 בספטמבר 2025 ב־02:00